mounjaro eli lilly tirzepatide FDA approval for Zepbound (tirzepatide) injection, the first and only obesity treatment of its kind that activates both GIP and GLP-1 hormone receptors - Lilly's Weight-Loss Drug Approved in

Adaptation to oxidative stress: quinone-mediated protection of signaling in rat lung epithelial L2 cells

It also modulates the activity of metalloproteinases (enzymes that break down extracellular matrix proteins) and their inhibitors, creating a balanced environment where damaged tissue is cleared while new tissue is being built

Body weight, insulin resistance severity, and metabolic goals also influence starting-dose selection

R.WestleyJ

For women trying to conceive: The FDA recommends discontinuing Zepbound at least 2 months before a planned pregnancy due to long half-life and unknown fetal effects, not because of fertility concerns